Argus Research analyst Kristina Ruggeri downgrades Beyond Meat (NASDAQ:BYND) from Hold to Sell.
HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $20 price target.